DICOTnews March 2026
The spring sun is shining outside the windows in Uppsala, and inside the Dicot Pharma office the activity level is high. Much of the focus is on preparations for the clinical phase 2b study planned to start in the second half of the year, including study design, protocol development and all other documentation required for the regulatory submission. Another important part is the manufacturing of the study drug, where we are now transitioning to a tablet formulation. Read more about this and other current updates in our latest newsletter.
Elin Trampe, CEO, Dicot Pharma
Tablet production starts for Phase 2b
We have now successfully developed the drug candidate LIB‑01 in tablet form, and production of the tablets for the upcoming Phase 2b clinical study has begun.
Here is the year-end report for 2025
On 18 February, the year-end report for 2025 was released, and in the filmed interview that followed we walked through the quarter’s key progress and other highlights.
Presentation at prestigious investor conference
At the end of February, Elin presented Dicot Pharma at the American investment bank Oppenheimer’s 36th Annual Healthcare Life Sciences Conference, an invitation only event where selected companies present to institutional investors from the industry.
A week in San Francisco
In January, Dicot Pharma took part in the annual J.P. Morgan Healthcare Conference week in San Francisco — arguably the most important global meeting place for companies seeking access to leading investors, partners, and decision makers in life science.
Q&A in a financial podcast
In an interview on the podcast Noterat produced by the financial magazine DI’s, Elin explained, among other things, why so many discontinue current treatments and how LIB 01 is increasingly linked to the growing longevity movement.
Biopharma predictions for 2026
Each year, the pharmaceutical publication Scrip asks executives, investors, and industry experts in biopharma for their strategic views on the year ahead. This time, Elin was one of the interviewees.
Do you want to receive press releases the moment they are published?
If you want to read our press releases as soon as they’re released, click the link below and fill in just two fields.